A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Clinical trial NCT02081378 · COMPLETED

Trial details

NCT number: NCT02081378
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Start date: 2014-04-24
Primary completion: 2021-06-03
Enrollment: 326

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.